GlassScriptPhysician profile
Howard B Reinfeld
NPI 1326070319
$3,406.32
in general payments reported to CMS, 2019-2025
30 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $521 · 2021: $358 · 2022: $639 · 2023: $579 · 2024: $531 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $663.60 | 2020-2024 | |
| Pfizer INC. | $477.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $331.03 | 2021-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $232.81 | 2023-2024 | Inpefa |
| Medtronic, INC. | $187.57 | 2022-2025 | Linq II |
| Amarin Pharma, INC. | $184.55 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $177.23 | 2019-2023 | Xarelto |
| Scpharmaceuticals INC. | $158.92 | 2025 | |
| Atricure, INC. | $145.57 | 2020 | |
| Edwards Lifesciences Corporation | $144.42 | 2020 | |
| Altathera Pharmaceuticals LLC | $126.48 | 2022 | |
| Angiodynamics, INC. | $118.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $87.51 | 2022-2024 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $72.66 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.11 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.51 | 2020-2023 | Trulicity |
| Impulse Dynamics (USA) INC. | $30.49 | 2024 | Optimizer |
| Sun Pharmaceutical Industries INC. | $23.67 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $21.95 | 2023 | Uptravi, Opsumit |
| Philips North America LLC | $18.75 | 2023 | |
| Medicure Pharma INC. | $18.67 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.07 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.88 | 2019 | |
| Glaxosmithkline, LLC. | $17.15 | 2019 | |
| Boston Scientific Corporation | $16.41 | 2024 | Watchman Access System |
| Eisai INC. | $16.25 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Reinfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.